NanoViricides Inc. (NNVC)

[seeker_of_value]

Injections yet to be developed?

The company said:"The Company’s initial indications for the drug are anticipated to be (a) a “piggy-back” solution for delivery via the customary IV infusion for hospitalized patients presenting with Influenza-Like-Illness (ILI), and (b) out-patient influenza. The Company continues to develop injectable formulations for both of these indications, as its first generation anti-influenza drugs."

This is the first time that I have understood that more work is needed in this area. They have an IV formulation for both hospitalized patients as well as outpatients. That may work for hospitalized ones, but will not work for outpatients. We must quickly develop injectable versions.